Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biotechnology company developing psychedelic-derived treatments for mental health conditions, in a deal that could reach up to USD 3.8 billion. The Lilly AtaiBeckley acquisition gives the Indianapolis-based pharmaceutical giant control of a Phase III-ready treatment-resistant depression therapy alongside two earlier-stage psychiatric assets, marking one of the largest pharmaceutical acquisitions in the emerging field of psychedelic-derived psychiatric medicines.
Under the terms of the agreement, Lilly will pay USD 6.75 per share in cash, valuing the upfront transaction at approximately USD 2.8 billion and representing a 26% premium to AtaiBeckley's previous closing price. Including contingent value rights, the deal could reach approximately USD 3.8 billion. Those contingent value rights are worth up to USD 2.50 per share (approximately USD 1 billion in aggregate), and are tied to future development and regulatory milestones. One milestone is tied to US regulatory approval of BPL-003 together with Drug Enforcement Administration rescheduling.
The centerpiece of the Lilly AtaiBeckley acquisition is BPL-003, an intranasal formulation of mebufotenin benzoate (5-MeO-DMT) that has advanced into a Phase III program for treatment-resistant depression under US FDA Breakthrough Therapy Designation following encouraging mid-stage clinical results. It is designed to produce rapid antidepressant effects from a single dose, with patients typically ready for clinic discharge within roughly two hours.
The BPL-003 clinical trial program now consists of two parallel pivotal studies, ReConnection 1 and ReConnection 2, following a successful End-of-Phase 2 meeting with the FDA earlier this year. The pipeline also includes VLS-01, a DMT buccal film in Phase IIb development, and EMP-01, an oral R-MDMA candidate in Phase IIa for social anxiety disorder.
The acquisition fits a pattern of Lilly using targeted, bolt-on deals to enter adjacent categories within neuroscience and related therapeutic areas. Lilly took a similar approach when it moved into sleep medicine through its USD 7.8 billion acquisition of Centessa, absorbing a clinical-stage asset and its supporting pipeline rather than building the capability internally.
For Lilly's broader neuroscience pipeline, the deal provides an entry point into a mechanism class the company has not previously prioritized. Treatment-resistant depression remains an area of significant unmet medical need, with existing options such as ketamine-derived therapies facing logistical limitations.